{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:30:16Z","timestamp":1787790616642,"version":"build-2784847793"},"reference-count":73,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T00:00:00Z","timestamp":1645315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["5 R42 ES026908 03"],"award-info":[{"award-number":["5 R42 ES026908 03"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["1R41ES032435-01"],"award-info":[{"award-number":["1R41ES032435-01"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["1R43GM139439-01"],"award-info":[{"award-number":["1R43GM139439-01"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Malignant melanoma is a lethal skin cancer containing melanoma-initiating cells (MIC) implicated in tumorigenesis, invasion, and drug resistance, and is characterized by the elevated expression of stem cell markers, including CD133. The siRNA knockdown of CD133 enhances apoptosis induced by the MEK inhibitor trametinib in melanoma cells. This study investigates the underlying mechanisms of CD133\u2019s anti-apoptotic activity in patient-derived BAKP and POT cells, harboring difficult-to-treat NRASQ61K and NRASQ61R drivers, after CRISPR-Cas9 CD133 knockout or Dox-inducible expression of CD133. MACS-sorted CD133(+) BAKP cells were conditionally reprogrammed to derive BAKR cells with sustained CD133 expression and MIC features. Compared to BAKP, CD133(+) BAKR exhibit increased cell survival and reduced apoptosis in response to trametinib or the chemotherapeutic dacarbazine (DTIC). CRISPR-Cas9-mediated CD133 knockout in BAKR cells (BAKR-KO) re-sensitized cells to trametinib. CD133 knockout in BAKP and POT cells increased trametinib-induced apoptosis by reducing anti-apoptotic BCL-xL, p-AKT, and p-BAD and increasing pro-apoptotic BAX. Conversely, Dox-induced CD133 expression diminished apoptosis in both trametinib-treated cell lines, coincident with elevated p-AKT, p-BAD, BCL-2, and BCL-xL and decreased activation of BAX and caspases-3 and -9. AKT1\/2 siRNA knockdown or inhibition of BCL-2 family members with navitoclax (ABT-263) in BAKP-KO cells further enhanced caspase-mediated apoptotic PARP cleavage. CD133 may therefore activate a survival pathway where (1) increased AKT phosphorylation and activation induces (2) BAD phosphorylation and inactivation, (3) decreases BAX activation, and (4) reduces caspases-3 and -9 activity and caspase-mediated PARP cleavage, leading to apoptosis suppression and drug resistance in melanoma. Targeting nodes of the CD133, AKT, or BCL-2 survival pathways with trametinib highlights the potential for combination therapies for NRAS-mutant melanoma stem cells for the development of more effective treatments for patients with high-risk melanoma.<\/jats:p>","DOI":"10.3390\/ijms23042333","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T08:18:05Z","timestamp":1645431485000},"page":"2333","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Employing CRISPR-Cas9 to Generate CD133 Synthetic Lethal Melanoma Stem Cells"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5070-0342","authenticated-orcid":false,"given":"Cynthia M.","family":"Simbulan-Rosenthal","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular & Cellular Biology, Georgetown University School of Medicine, Washington, DC 20057, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2273-0448","authenticated-orcid":false,"given":"Yogameenakshi","family":"Haribabu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular & Cellular Biology, Georgetown University School of Medicine, Washington, DC 20057, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Vakili","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular & Cellular Biology, Georgetown University School of Medicine, Washington, DC 20057, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Wei","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular & Cellular Biology, Georgetown University School of Medicine, Washington, DC 20057, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9066-7527","authenticated-orcid":false,"given":"Havens","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular & Cellular Biology, Georgetown University School of Medicine, Washington, DC 20057, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0330-0119","authenticated-orcid":false,"given":"Ryan","family":"Dougherty","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular & Cellular Biology, Georgetown University School of Medicine, Washington, DC 20057, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryyan","family":"Alobaidi","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular & Cellular Biology, Georgetown University School of Medicine, Washington, DC 20057, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2292-4960","authenticated-orcid":false,"given":"Bonnie","family":"Carney","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular & Cellular Biology, Georgetown University School of Medicine, Washington, DC 20057, USA"},{"name":"Firefighters\u2019 Burn and Surgical Laboratory, MedStar Health Research Institute, Washington, DC 20010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-6477","authenticated-orcid":false,"given":"Peter","family":"Sykora","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular & Cellular Biology, Georgetown University School of Medicine, Washington, DC 20057, USA"},{"name":"Amelia Technologies, LLC, 1121 5th St. NW, Washington, DC 20001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7624-0209","authenticated-orcid":false,"given":"Dean S.","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular & Cellular Biology, Georgetown University School of Medicine, Washington, DC 20057, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,20]]},"reference":[{"key":"ref_1","unstructured":"(2021, May 18). Surveillance, Epidemiology, and End Results Program, Cancer Stat Facts: Melanoma of the Skin, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.bbamcr.2016.01.025","article-title":"Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling","volume":"1863","author":"Paluncic","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ctrv.2016.03.003","article-title":"Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review","volume":"45","author":"Spagnolo","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","article-title":"Survival of patients with advanced metastatic melanoma: The impact of novel therapies-update 2017","volume":"83","author":"Ugurel","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.phrs.2016.07.017","article-title":"Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation","volume":"111","author":"Sandri","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_6","first-page":"326","article-title":"Chemotherapy Resistance Mechanisms in Advanced Skin Cancer","volume":"11","author":"Kalal","year":"2017","journal-title":"Oncol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nature11071","article-title":"Melanoma genome sequencing reveals frequent PREX2 mutations","volume":"485","author":"Berger","year":"2012","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nature08658","article-title":"A comprehensive catalogue of somatic mutations from a human cancer genome","volume":"463","author":"Pleasance","year":"2009","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e920957","DOI":"10.12659\/MSM.920957","article-title":"A review of the molecular pathways involved in resistance to BRAF inhibitors in patients with advanced-stage melanoma","volume":"26","author":"Tian","year":"2020","journal-title":"Med. Sci. Monit."},{"key":"ref_10","first-page":"488","article-title":"Treatment of metastatic melanoma: An overview","volume":"23","author":"Bhatia","year":"2009","journal-title":"Oncology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: A non-randomised, open-label phase 2 study","volume":"14","author":"Ascierto","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","article-title":"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: A phase 1 dose-escalation trial","volume":"13","author":"Falchook","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1517\/14712598.2015.1026323","article-title":"Trametinib in the treatment of melanoma","volume":"15","author":"Thota","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/1078-0432.CCR-14-1814","article-title":"A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1\/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors","volume":"21","author":"Bedard","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1007\/s10637-016-0377-0","article-title":"A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K\/mTOR inhibitor GSK2126458 in patients with advanced solid tumors","volume":"34","author":"Bedard","year":"2016","journal-title":"Investig. New Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1073\/pnas.1216013110","article-title":"Combined targeting of MEK and PI3K\/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo","volume":"110","author":"Posch","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/pcmr.12825","article-title":"A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma","volume":"33","author":"Nagler","year":"2020","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"969","DOI":"10.18632\/oncotarget.2824","article-title":"Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer","volume":"6","author":"Vujic","year":"2015","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1158\/1541-7786.MCR-14-0204","article-title":"Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma","volume":"12","author":"Vu","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/pcmr.12364","article-title":"Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK","volume":"28","author":"Vogel","year":"2015","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3389\/fendo.2016.00140","article-title":"Estrogen receptor beta in melanoma: From molecular insights to potential clinical utility","volume":"7","author":"Marzagalli","year":"2016","journal-title":"Front. Endocrinol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/jid.2015.198","article-title":"Combined inhibition of MEK and Plk1 has synergistic antitumor activity in NRAS mutant melanoma","volume":"135","author":"Posch","year":"2015","journal-title":"J. Investig. Derm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","article-title":"The BRAF and MEK inhibitors dabrafenib and trametinib: Effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4","volume":"21","author":"Liu","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Giampietri, C., Petrungaro, S., Cordella, M., Tabolacci, C., Tomaipitinca, L., Facchiano, A., Eramo, A., Filippini, A., Facchiano, F., and Ziparo, E. (2017). Lipid storage and autophagy in melanoma cancer cells. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18061271"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature06489","article-title":"Identification of cells initiating human melanomas","volume":"451","author":"Schatton","year":"2008","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3892\/ijo.2012.1590","article-title":"Clonal dominance of CD133+ subset population as risk factor in tumor progression and disease recurrence of human cutaneous melanoma","volume":"41","author":"Sharma","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"9328","DOI":"10.1158\/0008-5472.CAN-05-1343","article-title":"A tumorigenic subpopulation with stem cell properties in melanomas","volume":"65","author":"Fang","year":"2005","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2087204","DOI":"10.1155\/2016\/2087204","article-title":"The importance of CD44 as a stem cell biomarker and therapeutic target in cancer","volume":"2016","author":"Thapa","year":"2016","journal-title":"Stem Cells Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1038\/sj.onc.1206447","article-title":"Molecular plasticity of human melanoma cells","volume":"22","author":"Hendrix","year":"2003","journal-title":"Oncogene"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/modpathol.3800720","article-title":"Increased expression of stem cell markers in malignant melanoma","volume":"20","author":"Klein","year":"2007","journal-title":"Mod. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1158\/0008-5472.CAN-10-3997","article-title":"Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth","volume":"71","author":"Civenni","year":"2011","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/stem.1193","article-title":"ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets","volume":"30","author":"Luo","year":"2012","journal-title":"Stem Cells"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1038\/jid.2012.508","article-title":"Inhibition of the stem cell marker nestin reduces tumor growth and invasion of malignant melanoma","volume":"133","author":"Akiyama","year":"2013","journal-title":"J. Investig. Derm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1158\/0008-5472.CAN-10-1660","article-title":"VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth","volume":"71","author":"Frank","year":"2011","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.cell.2010.04.020","article-title":"A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth","volume":"141","author":"Roesch","year":"2010","journal-title":"Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMra043666","article-title":"Neural stem cells and the origin of gliomas","volume":"353","author":"Sanai","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1182\/blood.V90.12.5002","article-title":"AC133, a novel marker for human hematopoietic stem and progenitor cells","volume":"90","author":"Yin","year":"1997","journal-title":"Blood"},{"key":"ref_39","first-page":"5475","article-title":"Active fraction of Taiwanofungus camphoratus (HS7) exerted anticancer effects through multiple molecule targeting and elimination of cancer stem-like cells in lung cancer and hepatoma cells","volume":"69","author":"Lai","year":"2009","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/path.2283","article-title":"CD133: Molecule of the moment","volume":"214","author":"Mizrak","year":"2008","journal-title":"J. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.biocel.2004.08.010","article-title":"AC133\/CD133\/Prominin-1","volume":"37","author":"Shmelkov","year":"2005","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1071\/RD15432","article-title":"Prominin-1 glycosylation changes throughout early pregnancy in uterine epithelial cells under the influence of maternal ovarian hormones","volume":"29","author":"Dowland","year":"2017","journal-title":"Reprod. Fertil. Dev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"10946","DOI":"10.1158\/0008-5472.CAN-05-2018","article-title":"Prospective identification of tumorigenic prostate cancer stem cells","volume":"65","author":"Collins","year":"2005","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1525-1438.2007.01056.x","article-title":"Expression of CD133-1 and CD133-2 in ovarian cancer","volume":"18","author":"Ferrandina","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.stem.2007.06.002","article-title":"Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer","volume":"1","author":"Hermann","year":"2007","journal-title":"Cell Stem Cell"},{"key":"ref_46","first-page":"43","article-title":"Cancer Stem Cell Molecular Markers Verified in vivo","volume":"11","author":"Kim","year":"2017","journal-title":"Biochem. Suppl. Ser. B Biomed. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature05372","article-title":"A human colon cancer cell capable of initiating tumour growth in immunodeficient mice","volume":"445","author":"Pollett","year":"2007","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature05384","article-title":"Identification and expansion of human colon-cancer-initiating cells","volume":"445","author":"Lombardi","year":"2007","journal-title":"Nature"},{"key":"ref_49","first-page":"5821","article-title":"Identification of a cancer stem cell in human brain tumors","volume":"63","author":"Singh","year":"2003","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature03128","article-title":"Identification of human brain tumour initiating cells","volume":"432","author":"Singh","year":"2004","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.bbrc.2006.10.128","article-title":"Characterization of CD133+ hepatocellular carcinoma cells as cancer stem\/progenitor cells","volume":"351","author":"Suetsugu","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"7011","DOI":"10.1158\/0008-5472.CAN-04-1364","article-title":"Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma","volume":"64","author":"Galli","year":"2004","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/nature07567","article-title":"Efficient tumour formation by single human melanoma cells","volume":"456","author":"Quintana","year":"2008","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrc2108","article-title":"Reprogramming metastatic tumour cells with embryonic microenvironments","volume":"7","author":"Hendrix","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1158\/1078-0432.CCR-11-3237","article-title":"Molecular pathways: Vasculogenic mimicry in tumor cells: Diagnostic and therapeutic implications","volume":"18","author":"Kirschmann","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Mihic-Probst, D., Ikenberg, K., Tinguely, M., Schraml, P., Behnke, S., Seifert, B., Civenni, G., Sommer, L., Moch, H., and Dummer, R. (2012). Tumor cell plasticity and angiogenesis in human melanomas. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033571"},{"key":"ref_57","first-page":"19","article-title":"CD133 is associated with increased melanoma cell survival after multikinase inhibition","volume":"2019","author":"Gaur","year":"2019","journal-title":"J. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Simbulan-Rosenthal, C.M., Dougherty, R., Vakili, S., Ferraro, A.M., Kuo, L.-W., Alobaidi, R., Aljehane, L., Gaur, A., Sykora, P., and Glasgow, E. (2019). CRISPR-Cas9 knockdown and induced expression of CD133 reveal essential roles in melanoma invasion and metastasis. Cancers, 11.","DOI":"10.3390\/cancers11101490"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1158\/1541-7786.MCR-09-0383","article-title":"Overexpression of CD133 promotes drug resistance in C6 glioma cells","volume":"8","author":"Angelastro","year":"2010","journal-title":"Mol. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.1073\/pnas.1217002110","article-title":"Activation of PI3K\/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells","volume":"110","author":"Wei","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/sj.onc.1210811","article-title":"CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt\/PKB survival pathway","volume":"27","author":"Ma","year":"2008","journal-title":"Oncogene"},{"key":"ref_62","first-page":"304","article-title":"Interaction between CD133 and PI3K-p85 promotes chemoresistance in gastric cancer cells","volume":"10","author":"Song","year":"2018","journal-title":"Am. J. Transl. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"12576","DOI":"10.18632\/oncotarget.14990","article-title":"The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma","volume":"8","author":"Dakshanamurthy","year":"2017","journal-title":"Oncotarget"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Frederick, D.T., Fragomeni, R.A.S., Schalck, A., Ferreiro-Neira, I., Hoff, T., Cooper, Z.A., Haq, R., Panka, D.J., Kwong, L.N., and Davies, M.A. (2014). Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0101286"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11523-015-0391-8","article-title":"Heterodimeric bispecific single chain variable fragments (scFv) killer engagers (BiKEs) enhance NK-cell activity against CD133+ colorectal cancer cells","volume":"11","author":"Schmohl","year":"2016","journal-title":"Target. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1158\/1535-7163.MCT-11-0206","article-title":"Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer","volume":"10","author":"Waldron","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1080\/21691401.2018.1446969","article-title":"CD133-targeted delivery of self-assembled PEGylated carboxymethylcellulose-SN38 nanoparticles to colorectal cancer","volume":"46","author":"Alibolandi","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/carcin\/bgt479","article-title":"Id2, Id3 and Id4 overcome a Smad7-mediated block in tumorigenesis, generating TGF-beta-independent melanoma","volume":"35","author":"DiVito","year":"2014","journal-title":"Carcinogenesis"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1755-148X.2010.00758.x","article-title":"Smad7 restricts melanoma invasion by restoring N-cadherin expression and establishing heterotypic cell-cell interactions in vivo","volume":"23","author":"DiVito","year":"2010","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"72758","DOI":"10.18632\/oncotarget.11805","article-title":"Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL\/MMP-9 pathways in bladder cancer","volume":"7","author":"Falzone","year":"2016","journal-title":"Oncotarget"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3892\/ijo.2017.4015","article-title":"Tumor suppressor microRNA-34a inhibits cell migration and invasion by targeting MMP-2\/MMP-9\/FNDC3B in esophageal squamous cell carcinoma","volume":"51","author":"Yang","year":"2017","journal-title":"Int. J. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/exd.12582","article-title":"Inhibitor of differentiation-4 (Id4) stimulates pigmentation in melanoma leading to histiocyte infiltration","volume":"24","author":"DiVito","year":"2015","journal-title":"Exp. Dermatol."}],"updated-by":[{"DOI":"10.3390\/ijms27177643","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000}}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/4\/2333\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:00:23Z","timestamp":1787749223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/4\/2333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,20]]},"references-count":73,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["ijms23042333"],"URL":"https:\/\/doi.org\/10.3390\/ijms23042333","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,20]]}}}